{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:50:17Z","timestamp":1767826217333,"version":"3.49.0"},"reference-count":37,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cardiovascular disease (CVD) is a major underlying cause of death, with high economic burden in most countries, including the United States. Lifestyle modifications and the use of antiplatelet therapy, such as aspirin, can contribute significantly to secondary prevention of CVD in adults. This study examined the prevalence and associated factors of aspirin use for the secondary prevention of angina pectoris, myocardial infarction (MI), and cerebrovascular disease (stroke) in a sample of American adults. The 2015 Behavioral Risk Factor Surveillance System (BRFSS) dataset was analyzed for this cross-sectional study. Almost 16% of the study population (N = 441,456) had angina, MI, or stroke. Weighted percentages of respondents with angina, MI, and stroke were 4%, 4.3%, and 3%, respectively. Overall, weighted prevalence of daily (or every other day) aspirin use was about 65%, 71%, and 57% among respondents with angina, MI, and stroke, respectively. Factors that were significantly associated with aspirin use included male sex, more than high school education, high blood pressure, diabetes, and less than excellent general health. There were existing differences among individuals with CVD based on diagnosis, demographic and socioeconomic status in the use of aspirin for secondary prevention. Resources for promoting aspirin use should be directed toward groups with lower utilization.<\/jats:p>","DOI":"10.3390\/jcm8020264","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T11:45:39Z","timestamp":1550663139000},"page":"264","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Aspirin Use among Adults with Cardiovascular Disease in the United States: Implications for an Intervention Approach"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-974X","authenticated-orcid":false,"given":"Benjamin E.","family":"Ansa","sequence":"first","affiliation":[{"name":"Institute of Public &amp; Preventive Health, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Master of Science in Experimental Psychology Program, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicollette","family":"Lewis","sequence":"additional","affiliation":[{"name":"Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Savoy","sequence":"additional","affiliation":[{"name":"Burke Medical Center of Waynesboro, Waynesboro, GA 30830, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Hickson","sequence":"additional","affiliation":[{"name":"Master of Public Health Program, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6172-4358","authenticated-orcid":false,"given":"Rebecca","family":"Stone","sequence":"additional","affiliation":[{"name":"Institute of Public &amp; Preventive Health, Augusta University, Augusta, GA 30912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Johnson","sequence":"additional","affiliation":[{"name":"Belvedere Elementary School, Aiken County Public School District, N. Augusta, SC 29841, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"ref_1","unstructured":"(2018, August 07). WHO Cardiovascular Diseases (CVDs). Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/."},{"key":"ref_2","unstructured":"Mendis, S., Puska, P., and Norrving, B. (2011). Global Atlas on Cardiovascular Disease Prevention and Control, World Health Organization."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stewart, J., Manmathan, G., and Wilkinson, P. (2017). Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc. Dis., 6.","DOI":"10.1177\/2048004016687211"},{"key":"ref_4","unstructured":"Benjamin, E.J., Blaha, M.J., Chiuve, S.E., Cushman, M., Das, S.R., Deo, R., de Ferranti, S.D., Floyd, J., Fornage, M., and Gillespie, C. (2013). On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics\u20142017 update: A report from the American Heart Association [published online ahead of print January 25, 2017]. Circulation."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_6","first-page":"63","article-title":"AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"2014","author":"Eckel","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","first-page":"179","article-title":"The discovery of aspirin\u2019s antithrombotic effects","volume":"34","author":"Miner","year":"2007","journal-title":"Tex. Heart Inst. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3121\/cmr.2013.1197","article-title":"The role of aspirin in the prevention of cardiovascular disease","volume":"12","author":"Ittaman","year":"2014","journal-title":"Clin. Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: Cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br. J. Clin. Pharmaco."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000077340","article-title":"What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?","volume":"17","author":"Dippel","year":"2004","journal-title":"Cerebrovasc. Dis."},{"key":"ref_12","unstructured":"(2018, August 07). Final Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. Available online: https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/aspirin-to-prevent-cardiovascular-disease-and-cancer."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Guirguis-Blake, J.M., Evans, C.V., Senger, C.A., Rowland, M.G., O\u2019Connor, E.A., and Whitlock, E.P. (2015). Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 131.","DOI":"10.7326\/M15-2113"},{"key":"ref_14","unstructured":"American Heart Association (2018, August 07). Aspirin and Heart Disease. Available online: http:\/\/www.heart.org\/HEARTORG\/Conditions\/HeartAttack\/PreventionTreatmentofHeartAttack\/Aspirin-and-Heart-Disease_UCM_321714_Article.jsp#.W2oJHMIpC70."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"208221","DOI":"10.1016\/j.cjca.2010.12.033","article-title":"The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary","volume":"27","author":"Bell","year":"2011","journal-title":"Can. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2007.08.024","article-title":"ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary","volume":"194","author":"Graham","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2, 349\u2013360.","DOI":"10.1016\/S0140-6736(88)92833-4"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.14503\/THIJ-16-5807","article-title":"Aspirin for Primary and Secondary Prevention of Cardiovascular Disease","volume":"43","author":"Godley","year":"2016","journal-title":"Tex. Heart Inst. J."},{"key":"ref_19","unstructured":"(2018, August 08). Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System (BRFSS), Available online: http:\/\/www.cdc.gov\/brfss\/about\/index.htm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.5888\/pcd14.170171","article-title":"Aspirin for Prevention of Cardiovascular Disease","volume":"14","author":"Mendy","year":"2017","journal-title":"Prev. Chronic. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ansa, B.E., White, S., Chung, Y., and Smith, S.A. (2016). Trends in HIV Testing among Adults in Georgia: Analysis of the 2011-2015 BRFSS Data. Int. J. Environ. Res. Public Health, 13.","DOI":"10.3390\/ijerph13111126"},{"key":"ref_22","unstructured":"American Association for Public Opinion Research (2016, October 25). Standard Definitions, Available online: https:\/\/www.aapor.org\/AAPOR_Main\/media\/publications\/Standard-Definitions2015_8theditionwithchanges_April2015_logo.pdf."},{"key":"ref_23","unstructured":"Centers for Disease Control and Prevention (2016, October 25). Behavioral Risk Factor Surveillance System, Available online: http:\/\/www.cdc.gov\/brfss\/annual_data\/2015\/pdf\/2015-sdqr.pdf."},{"key":"ref_24","unstructured":"Centers for Disease Control and Prevention (2016, October 25). Behavioral Risk Factor Surveillance System, Available online: https:\/\/www.cdc.gov\/brfss\/annual_data\/2014\/pdf\/weighting-data.pdf."},{"key":"ref_25","unstructured":"The Complete Guide to Market Research (2019, February 07). Data Preparation. Available online: https:\/\/www.qresearchsoftware.com\/market-research-guide-data-preparation."},{"key":"ref_26","unstructured":"IBM Corp (2017). Released 2017. IBM SPSS Statistics for Windows, Version 25.0, IBM Corp."},{"key":"ref_27","first-page":"30","article-title":"Centers for Disease Control and Prevention. Public health surveillance data: Legal, policy, ethical, regulatory, and practical issues","volume":"61","author":"Bernstein","year":"2012","journal-title":"MMWR Suppl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e002320","DOI":"10.1161\/JAHA.115.002320","article-title":"Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980\u20132009: The Minnesota Heart Survey","volume":"4","author":"Luepker","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_29","first-page":"733","article-title":"Use of Aspirin for Prevention of Recurrent Atherosclerotic Cardiovascular Disease Among Adults\u201420 States and the District of Columbia, 2013","volume":"64","author":"Fang","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2015.01.014","article-title":"Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012)","volume":"115","author":"Fang","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11606-007-0116-5","article-title":"Gender differences in aspirin use among adults with coronary heart disease in the United States","volume":"22","author":"Opotowsky","year":"2007","journal-title":"J. Gen. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pmedr.2016.12.023","article-title":"Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012\u20132015","volume":"5","author":"Stuntz","year":"2017","journal-title":"Prev. Med. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.7326\/0003-4819-142-11-200506070-00015","article-title":"An editorial update: Should she take aspirin?","volume":"142","author":"Mulrow","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Drug therapy\u2014Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N. Eng. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(18)31990-1","article-title":"Aspirin for primary prevention of cardiovascular disease","volume":"392","author":"Capodanno","year":"2018","journal-title":"Lancet"},{"key":"ref_37","unstructured":"Barrett-Connor, E., Ayanian, J.Z., Brown, E.R., Coultas, D.B., Francis, C.K., Goldberg, R.J., Gostin, L.O., Kottke, T.E., Lee, E.T., and Mannino, D.M. (2011). A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases, National Academies Press (U.S.)."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/2\/264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:33:26Z","timestamp":1760186006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/2\/264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["jcm8020264"],"URL":"https:\/\/doi.org\/10.3390\/jcm8020264","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]}}}